Cystic Fibrosis Foundation
207
32
38
141
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.2%
15 terminated/withdrawn out of 207 trials
90.4%
+3.8% vs industry average
11%
23 trials in Phase 3/4
43%
60 of 141 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (207)
HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy
Role: collaborator
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Role: collaborator
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
Role: collaborator
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection
Role: collaborator
Clearance in Primary Ciliary Dyskinesia
Role: collaborator
Rethinking Early Airway Clearence Therapies
Role: collaborator
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Role: collaborator
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Role: collaborator
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
Role: collaborator
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
Role: collaborator
Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
Role: collaborator
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Role: collaborator
Bionic Pancreas in CFRD
Role: collaborator
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
Role: collaborator
COVID-19 Antibody Responses In Cystic Fibrosis
Role: collaborator
Rare CFTR Mutation Cell Collection Protocol (RARE)
Role: collaborator
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
Role: collaborator
Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
Role: collaborator
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Role: collaborator
The PROMISE Pediatric Study 6 to 11 Years Old
Role: collaborator